Attenuated Zika, Dengue and West Nile mutant virus for development of high-efficiency vaccines


Mutation in NS3, a protein conserved across all 4 types of Dengue, Zika, and West Nile viruses, significantly inhibits replication and host immune suppression, but retains infectivity similar to wild-type virues. Therefore, NS3-based virus attenuation offers significant advantages as a vaccine candidate due to its low virulence and high virus-specific immunogenicity compared to current vaccine candidates that rely on inactivated viruses or viral chimeras. A recombinant, attenuated vaccine can be developed and produced within current vaccine development and manufacturing pipelines, and it may quickly occupy a significant share of the market due to optimal clinical outcome.

Intellectual Property Status: Patent(s) Pending